Abstract
Although cytomegalovirus (CMV) infection is common, the majority of infections cause little or no symptoms. Serious disease occurs virtually exclusively in fetuses or neonates and immunosuppressed individuals including those on corticosteroids, transplant recipients, and those with the acquired immunodeficiency syndrome (AIDS). Retinitis, gastrointestinal disease, and interstitial pneumonitis are among the more common manifestations of CMV disease, but infections at other sites also occur.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Shepp DH, Dandliker PS, Miranda P, et al. “Activity of 9-[2-Hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the Treatment of Cytomegalovirus Pneumonia.” Annals of Internal Medicine. 1985; 103: 368–373.
Grundy, J. “Virologie and Pathogenetic Aspects of Cytomegalovirus Infections.” Reviw of Infectious Diseases. 1990; 12 (Suppl. 7): S711–9.
Meyers JD, Floumoy N, Thomas ED. “Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation.” Journal of Infectious Diseases. 1986; 153: 478–88.
Bratanow NC, Ash RC, Turner PA, et al. “Successful Treatment of Serious Cytomegalovirus Disease with 9 (1,3-dihydroxy-2-propoxymethyl) Guanine in Bone Marrow Transplant Patients. Blood. 1986;68 Suppl. 1: 280a
Emanual D, Cunningham I, Jules-Eleysee K, et al. “Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin.” Annals of Internal Medicine. 1988; 109: 777–82.
Reed EC, Bowden RA, Dandliker PS, et al. “Treatment of Cytomegaaovins Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow Transplants.” Annals of Internal Medicine. 1988; 109; 783–8.
Schmidt GM, Kovacs A, Zaia JA, et al. “Ganciclovir/Immunoglobulin Combination Therapy for the Treatment of Human Cytomegalovirus-Associated Interstitial Pneumonia in Bone Marrow Allograft Recipients.” Transplantation. 1988; 46: 905–7.
Crawford SW, Bowden RA, Hackman RC, et al. “Rapid Detection of Cytomegalovirus Pulmonary Infection by Bronchoalveolar Lavage and Centrifugation Culture.” Annals of Internal Medicine. 1988; 108: 180–5.
Emanual DJ. “Uses of Immunotherapy for Control of Human Cytomegalovirus-Associated Dicrases.” Transplantation Proceedings. 1991;23,Suppl 3: 144–6.
Chatenoud L. “The Immune Response Against Therapeutic Monoclonal Antibodies.” Immunology Today. 1986; 7: 367–8.
Khazaeli MB, Mansoor NS, Wheeler RH, et al. “Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17–1A. II. Pharmacokinetics and Immune Response.” Journal of the National Cancer Institute. 1988; 80: 937–42.
Aulitzky WE, Schulz TF, Tilg H, et al. “Human Monoclonal Antibodies Neutralizing Cytomegalovirus (CMV) for Prophylaxis of CMV Disease: Report of a Phase I Trial in Bone Marrow Transplant Recipients.” Journal of Infectious Diseases. 1991;163:1344–7_
Azuma J, Kurimoto T, Tsuji S, et al. “Phase I Study on Human Monoclonal Antibody Against Cytomegalovirus: Pharmacokinetics and Immunogenicit.” Journal of Immunotherapy. 1991; 10: 278–85.
Hagenbeek A, Brummelhuis HGJ, Donkers A, et al. “Rapid Clearance of Cytomegalovirus-Specific IgG After Repeated Intravenous Infusions of Human Immunoglobulin into Allogeneic Bone Marrow Transplant Recipients.” Journal of Infectious Diseases. 1987; 155: 897–902.
Petersen E, Kaplan C, Fish D, et al. “Human Monoclonal Antibody to Cytomegalvirus (TI-23): Pharmacokinetics and Toxicity Study in HIV Seropositive Patients.” Sixth International Conference on AIDS. June 20, 1990.
Pollard RB, Nokta MA, Pappas P, et al. “A Phase I/IIA Study of a Human Monoclonal Anti-Cytomegalovirus Antibody in Patients with AIDS.” Antiviral Research, 1992;16, Suppl 1: 111.
Tolpin M, Pollard R, Tierney M, et al. “Combination Therapy of Cytomegalovirus (CMV) Retinitis with a Human Monocloncal Anti-CMV Antibody (SDZ MSL 109) and Either Ganciclovir (DHPG) or Foscarnet (PFA).” IXth International Conference on AIDS. June 6–11, 1993.
Quitman GV, Kimiani N, Rood AH, et al. “Cytotoxic T Cells in Cytomegalovirus Infection.” New England Journal of Medicine. 1982; 307: 7–13.
Greenberg PD, Renccer P, Goodrich JM, et al. “Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Receipients by Adoptive Transfer of Donor-Derived CMV-Specific T Cell Clones Expanded In Vitro Annals New York Academy of Sciences. 1991; 636: 184–95.
Riddell SR, Watanabe KS, Goodrich JM, et al. “Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones.” Science. 1992; 257: 238–41.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Paar, D.P., Pollard, R.B. (1996). Immunotherapy of CMV Infections. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 4. Advances in Experimental Medicine and Biology, vol 394. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9209-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9209-6_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9211-9
Online ISBN: 978-1-4757-9209-6
eBook Packages: Springer Book Archive